We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Arkivum Limited is a cloud-based Software as a Service (SaaS) that provides specialist digital archiving and preservation services to customers in highly regulated industries, such as pharmaceuticals. Arkivum asserts that its software ensures that the digital content of its customers is safeguarded, usable, and auditable for decades into the future. Arkivum argues that its focus area is archiving clinical trial data for pharmaceutical companies, centring around Electronic Trial Master File (eTMF) that contain tens of thousands of different types of documents and overseen closely by drug sponsors. The company further claims that its services triumph over those offered by Amazon Web Services (AWS), Google Cloud Platform (GCP) and Microsoft Azure. Arkivum points out that its services have led to the company earning £1.4 million as Annual Recurring Revenue (ARR) as of March 2021. Arkivum is seeking to raise up to £1.075 million of equity to grow its business across different verticals.
days to go: Expired investment: Withheld
Ceryx Medical is a medical technological entity that is developing bioelectronics based on a unique, patent-protected, chip technology that can mimic nerve centres within the body called Central Pattern Generators (CPGs). CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate, and even walking. The Ceryx system resembles a traditional cardiac pacing device that holds a lot of promise in potentially alleviating incidences of heart failure leading to a therapeutic effect on patient health. In the UK, this is a day surgery procedure under local anaesthetic with a basic system costing around £3500. The device, therefore, offers a cost-effective, single procedure solution for this currently intractable disease. Treatment expenditures on heart failure cases in the EU amount to almost £35 billion. The Ceryx system is a potential disruptor in this segment and offers multiple potential applications. The company is targeting £500,000 as part of £1 million round. With the investment, the company aims to produce a data package that mimics those used to support 510k/NDA applications, as mandated by the US Food and Drug Administration (FDA), for current devices and drugs used to treat heart failure.
days to go: Expired investment: Withheld
Elute Intelligence is an online platform that makes searching documents fast, simple, and accurate. The platform is optimised to handle a variety of tasks such as plagiarism detection, patent searching, fraud detection, governance and compliance, and e-discovery to name a few. Using a unique AI-based system, users can upload long-form documentation, and the system will analyse, tag, and find related articles across a wide range of academic journals and data sources. The company is looking to engage in partnerships: with government and commercial R&D teams to help accelerate research into Covid-19, with development partners to help expand the system into other research areas, and with investors interested in an AI and big data platform that can transform scientific research processes.

Pitch Rated

40%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Bodytrak is a wearable technology that monitors physiological activity such as heart rate and core body temperature.  This real time data is analysed using cloud based technology and algorithms to supervisors or commanders so early action can be taken on the event of illness or injury.
days to go: Expired investment: £1,123,119
Invluencer is a Venture Capital (VC) company with an economic model designed to bring VC to the masses. Invluencer believes in boosting greater investment capability between investors and company representatives. This is undertaken by creating a smart-contract enabled 'Intelligent Wallet' for autonomous investment in vetted high-growth companies facilitated by Invluencer’s unique Multi-Asset Platform (I-MAP) and Intelligent Distributed Due Diligence (i3D) platform. Through these platforms, the company aims to simplify investment and open liquidity between worthy companies and accredited investors. The company will use the investments to continue the development of due diligence and fund management platforms, strengthen the investment team and analysis team, strengthen relationships and partnerships within the VC ecosystem.

Pitch Rated

43%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £154,000
Percayso is a Business-to-Business (B2B) insurance technology entity that aims to become a contender in the £220 billion per year UK insurance industry. The company claims that conventional methods of finding the best insurance premiums has its share of hurdles. Percayso intends to change this. It points out that its portal allows users to find relevant premiums, reduce chances of fraud and increase profit, all in a transparent layout. The company has already signed four clients. It argues that it has a strong pipeline of 25+ opportunities and aims to convert at least 50% of these. It will use 45% of the investment for platform development, 20% for third party integrations, 20% as working capital, 10% for product and international development, and 5% for marketing and networking.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £437,134
OneSub uses Artificial Intelligence (AI) to understand thousands of articles a day and provides a customized news source that promotes difference of ideas. It monitors the reading history of the users and fills in any knowledge gaps. OneSub also provides alternative content from Facebook, Apple news and many more. The company has developed and expanded a working prototype of the platform. The funds will be used for product and team expansion.
days to go: Expired investment: £106,812
Thyngs is a revolutionary, self-service platform that enables marketers to transform any of their physical marketing assets into an instant point-of-sale, giving retailers, re-seller partners, publishers, and charities the ability to create new services in a matter of minutes. Its simple, secure, and unique 3-tap payment process is similar to Apple Pay. Many reputed companies like Wasabi, Warner Bros, National Geographic, and Monster Energy have already worked with Thyngs. Moreover, the company aggregates various partners such as Apple Pay, PayPal, and Google Pay. The company's typical ROI is more than 500%. With the proceeds, Thyngs will work with PWC as part of its Raise programme and engage with several Series A VC funds to raise £3-4m in early 2020.
days to go: Expired investment: £361,162
Thyngs are a technology company that transform anything into an instant point of sale through the use of QR and NFC tags. This means consumers can purchase anything without going to a till.
days to go: Expired investment: £301,310
EDGE10 aim to advance human performance in the most challenging arenas. They use data solutions to analyse and optimise the performance of athletes and teams in the global sports industry which was worth US$1,274 trillion in 2016. 
days to go: Expired investment: £454,463
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph